Novo nordisk to acquire ocedurenone for uncontrolled hypertension from kbp biosciences

BagsvÆrd, denmark and singapore, 16 october 2023 – novo nordisk a/s and kbp biosciences pte., ltd. today announced that novo nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from kbp biosciences for up to 1.3 billion us dollars.
NVO Ratings Summary
NVO Quant Ranking